Table 1.
Clinical characteristics of systemic lupus erythematosus (SLE) patients.
| SLE | Controls | |
|---|---|---|
| Sex (F/M) | 32/2 | 32/2 |
| Age (years, mean ± SD) | 35.2 ± 2.1 | 33.6 ± 3.3 |
| Disease duration (years) | 4.47 ± 1.3 | |
| Treatment | ||
| Methotrexate | 21 | |
| Prednisone | 22 | |
| Antimalarials | 16 | |
| Mycophenolate | 5 | |
| Azathioprine | 4 | |
| Cyclosporine | 2 | |
| SLEDAI (mean ± SD) | 5.9 ± 0.8 | |
| SLEDAI ≥ 8 | 12 | |
| SLEDAI ≤ 8 | 20 |
Dosage: methotrexate 12.5–20 mg/week; prednisone 5–10 mg/day; chloroquine 150–300 mg/day; azathioprine 100 mg/day; mycophenolate mofetil 2 g/day; and cyclosporine 50–100 mg/day weight adjusted.